Now showing items 13-16 of 16

    • Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. 

      Seibert, Tyler M; Fan, Chun Chieh; Wang, Yunpeng; Zuber, Verena; Karunamuni, Roshan; Parsons, J Kellogg; Eeles, Rosalind A et al. (BMJ, 2018-01-10)
      Objectives: Prostate-specific-antigen (PSA) screening resulted in reduced prostate cancer (PCa) mortality in a large clinical trial, but due to many false positives and overdiagnosis of indolent disease, many guidelines ...
    • Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy: a case report 

      Janowitz, Tobias; Welsh, Sarah; Warren, Anne Y; Robson, Jane; Thomas, Benjamin; Shaw, Ashley; Ainsworth, Nicola L et al. (BioMed Central, 2015-10-01)
      Background: Non-seminomatous germ cell tumours make up about 40% of all germ cell tumours, which in turn are the most common tumours in men aged 15-44 years. Low risk stage I nonseminomatous germ cell tumours, which are ...
    • Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort 

      Bonilla, Carolina; Lewis, Sarah J; Martin, Richard M; Donovan, Jenny L; Hamdy, Freddie C; Neal, David E; Eeles, Rosalind et al. (BioMed Central, 2016-04-04)
      Background: Epidemiological studies have observed a positive association between an earlier age at sexual development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational estimates ...
    • Response of Degarelix treatment in human prostate cancer monitored by HR-MAS $^{1}$H NMR spectroscopy 

      Madhu, Madhu; Shaw, Greg L; Warren, Anne Y; Neal, David E; Griffiths, John Richard (Springer, 2016-06-30)
      $\textit{Introduction}$ The androgen receptor (AR) is the master regulator of prostate cancer cell metabolism. Degarelix is a novel gonadotrophin-releasing hormone blocker, used to decrease serum androgen levels in order ...